Symbol="ACHL"
AssetType="Common Stock"
Name="Achilles Therapeutics PLC ADR"
Description="Achilles Therapeutics Plc, a clinical-stage immuno-oncology biopharmaceutical company, develops precision T-cell therapies to treat various types of solid tumors. The company is headquartered in London, the United Kingdom."
CIK="1830749"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="245 HAMMERSMITH ROAD, LONDON, GB"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="39202700"
EBITDA="-67022000"
PERatio="None"
PEGRatio="None"
BookValue="4.523"
DividendPerShare="0"
DividendYield="0"
EPS="-1.83"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.177"
ReturnOnEquityTTM="-0.316"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.83"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="8.8"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="0.263"
EVToRevenue="-"
EVToEBITDA="1.59"
Beta="0.927"
num_52WeekHigh="3.45"
num_52WeekLow="0.75"
num_50DayMovingAverage="0.957"
num_200DayMovingAverage="1.327"
SharesOutstanding="40938500"
DividendDate="None"
ExDividendDate="None"
symbol="ACHL"
open="0.96"
high="0.98"
low="0.94"
price="0.96"
volume="26871.00"
latest_trading_day="2023-07-05"
previous_close="0.94"
change="0.02"
change_percent="1.8723%"
aroon_positive_momentum_days="38"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="38"
Volume_recent_avg="150915"
Change_recent_avg="-0.01"
Delta_recent_avg="0.06"
Variance_recent_avg="0.03"
Change_ratio_recent_avg="-0.99"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="38"
Aroon_momentum_negative="62"
image_negative_thumbnail_id_1="155"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0021.jpeg"
image_negative_thumbnail_id_2="166"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0010.jpeg"
image_neutral_thumbnail_id_1="584"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0015.jpeg"
image_neutral_thumbnail_id_2="530"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0069.jpeg"
image_positive_thumbnail_id_1="630"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0078.jpeg"
image_positive_thumbnail_id_2="611"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0097.jpeg"
image_professor_thumbnail_id_1="1196"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0030.jpeg"
image_professor_thumbnail_id_2="1202"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0036.jpeg"
